BEAM Beam Therapeutics Inc. Common Stock Loading...

Loading chart...
Top Calls
Feed
All Sources✓
YouTube✓
Twitter✓
Reddit✓
Substack✓
Insider✓
Loading...
0 selected
All Content✓
Source feeds
Buzzberg's Top 50 ✓
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
23:56
Apr 28
Jim Cramer Host, Mad Money CNBC
Beam is too speculative, avoid.
Beam Therapeutics is a speculative, heavily shorted biotech with no earnings. Unless they have something that saves lives, move on.
BEAM 1ST
MED
21:52
Mar 02
Becky Quick Co-Anchor, Squawk Box CNBC
In the outro, Becky Quick teases the next episode featuring a child who received a "personalized CRISPR-based gene editing therapy" that likely saved his life. While a teaser, this highlights the shift of CRISPR technology from theoretical research to applied clinical success ("miracles"). Positive real-world outcomes in rare diseases validate the platforms of major gene-editing companies, justifying premium valuations for their pipelines. Long the CRISPR innovators as clinical validation accelerates. Regulatory hurdles; high cost of personalized therapies limiting total addressable market (TAM).
BEAM

About BEAM Analyst Coverage

Buzzberg tracks BEAM (Beam Therapeutics Inc. Common Stock) across 1 sources. 0 bullish vs 0 bearish calls from 2 analysts. Sentiment: evenly split. 2 total trade ideas tracked.